Brief: Monte Rosa Therapeutics Provides Corporate Update And Key Anticipated Milestones For 2024
08/01/2024 14:22
Jan 8 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS PROVIDES CORPORATE UPDATE AND KEY
ANTICIPATED MILESTONES FOR 2024
* MONTE ROSA THERAPEUTICS INC - CASH POSITION EXPECTED TO
FUND
OPERATIONS INTO H1 2026
* MONTE ROSA THERAPEUTICS: GOT US FDA FAST TRACK DESIGNATION
FOR
MRT-2359 FOR PREVIOUSLY TREATED, METASTATIC SMALL CELL LUNG
CANCER
* MONTE ROSA THERAPEUTICS INC- EXPECTS TO SUBMIT AN IND FOR
MRT-6160, A VAV1-TARGETED MGD, IN FIRST HALF OF 2024
Source text for Eikon: ID:nGNX44FmLY
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million